A case of high‐risk AML in a patient with advanced systemic mastocytosis

Aggressive SM + AML has limited therapeutic options. Even a strong combination of decitabine–venetoclax–midostaurin has a transient effect on AML and a mitigated effect on SM. Larger series are required to identify the best therapeutic strategy.

Detalles Bibliográficos
Autores principales: Fazio, Manlio, Vetro, Calogero, Markovic, Uroš, Duminuco, Andrea, Parisi, Marina, Maugeri, Cinzia, Mauro, Elisa, Parrinello, Nunziatina Laura, Stagno, Fabio, Villari, Loredana, Triolo, Anna Maria, Stella, Stefania, Palumbo, Giuseppe A., Di Raimondo, Francesco, Romano, Alessandra, Zanotti, Roberta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10352544/
https://www.ncbi.nlm.nih.gov/pubmed/37469366
http://dx.doi.org/10.1002/ccr3.7134

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10352544/
https://www.ncbi.nlm.nih.gov/pubmed/37469366
http://dx.doi.org/10.1002/ccr3.7134

Ejemplares similares